Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs Allbirds Inc (BIRD) Price & Performance

Biogen IncTrade
Allbirds IncTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Allbirds Inc — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Allbirds Inc trades at $2.6 (market cap $30.00M). The key difference: Biogen Inc is far larger — about 1004.3× Allbirds Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.

BIIBBIRD
Market Cap
$30.13B$30.00M
Sector
HealthConsumer Cyclical
52-Week High
$216.63$16.99
52-Week Low
$128.93$2.21
Enterprise Value
$37.20B$48.86M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

No Aura AI signal available yet.

Allbirds Inc

BIRD trades at $2.58, up 1.98% today, amid a strategic pivot from footwear to AI infrastructure, rebranding as Smartbird. Despite negative profitability and cash burn, the stock shows bullish technical signals and surged on recent leadership changes. Revenue has declined from $298M in 2022 to $152M in 2025, with net losses persisting but improving from -$152M to -$77M over the period.

Outlook hinges on successful AI transition, but high execution risk and sustained losses warrant caution. Analysts are mostly neutral, with 79% hold ratings. The stock offers speculative upside if new strategy gains traction, yet faces significant financial and competitive headwinds.

Returns comparison

Trailing returns across standard periods

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD